Satomi Niwayama

Dr. Satomi Niwayama

Graduate School of Engineering, Muroran Institute of Technology, Muroran, Hokkaido 050-8585, Japan
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EGEric C. Griffith
Eric C. Griffith
ZSZhuang Su
Zhuang Su
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama
CRCameron A. Ramsay
Cameron A. Ramsay
Yie-Hwa ChangYie-Hwa Chang
Yie-Hwa Chang
JLJun O. Liu
Jun O. Liu
Angiogenesis inhibitors are a novel class of promising therapeutic agents for treating cancer and other human diseases. Fumagillin and ovalicin compose a class of structurally related natural products that potently inhibit angiogenesis by blocking endothelial cell proliferation. A synthetic analog of fumagillin, TNP-470, is currently undergoing clinical trials for treatment of a variety of cancers. A common target for fumagillin and ovalicin recently was identified as the type 2 methionine aminopeptidase (MetAP2). These natural products bind MetAP2 covalently, inhibiting its enzymatic activity. The specificity of this binding is underscored by the lack of inhibition of the closely related type 1 enzyme, MetAP1. The molecular basis of the high affinity and specificity of these inhibitors for MetAP2 has remained undiscovered. To determine the structural elements of these inhibitors and MetAP2 that are involved in this interaction, we synthesized fumagillin analogs in which each of the potentially reactive epoxide groups was removed either individually or in combination. We found that the ring epoxide in fumagillin is involved in the covalent modification of MetAP2, whereas the side chain epoxide group is dispensable. By using a fumagillin analog tagged with fluorescein, His-231 in MetAP2 was identified as the residue that is covalently modified by fumagillin. Site-directed mutagenesis of His-231 demonstrated its importance for the catalytic activity of MetAP2 and confirmed that the same residue is covalently modified by fumagillin. These results, in agreement with a recent structural study, suggest that fumagillin and ovalicin inhibit MetAP2 by irreversible blockage of the active site.

1 January 1996 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama
EKE. Adam Kallel
E. Adam Kallel
DSDavid C. Spellmeyer
David C. Spellmeyer
CSChimin Sheu
Chimin Sheu
KHK. N. Houk
K. N. Houk

30 January 1998 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
JLJian Liu
Jian Liu
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama
YYYing You
Ying You
KHK. N. Houk
K. N. Houk

11 August 2000 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama

1 January 1996 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama
BTBenjamin E. Turk
Benjamin E. Turk
JLJun O. Liu
Jun O. Liu

1 January 1996 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama
EKE. Adam Kallel
E. Adam Kallel
CSChimin Sheu
Chimin Sheu
KHK. N. Houk
K. N. Houk